Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22809604 | 0.82 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL19083678 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL14051590 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL11078962 | 0.80 | SMN1; SMN2 (0.53) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL13197550 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL16592103 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL22809581 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL3649246 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL19083879 | 0.78 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL1926743 | 0.78 | SMN1; SMN2 (0.52) | CYP1A2CYP3A4CYP2C19RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | CYP1A2 2057/4885CYP3A4 2509/4885CYP2C19 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.